Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

5.73
-0.1500-2.55%
Post-market: 5.70-0.0300-0.52%19:09 EDT
Volume:944.59K
Turnover:5.41M
Market Cap:344.57M
PE:-1.41
High:5.93
Open:5.88
Low:5.61
Close:5.88
52wk High:9.94
52wk Low:4.14
Shares:60.14M
Float Shares:54.20M
Volume Ratio:0.92
T/O Rate:1.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0548
EPS(LYR):-3.7413
ROE:-60.48%
ROA:-18.81%
PB:1.23
PE(LYR):-1.53

Loading ...

Vanda Pharmaceuticals SVP, General Counsel and Secretary Daniel McGuire files initial beneficial ownership statement

Reuters
·
Jun 09

Vanda Pharmaceuticals Inc - Japan Grants Orphan Drug Designation to Imsidolimab for Generalized Pustular Psoriasis

THOMSON REUTERS
·
May 27

Japan health ministry grants orphan drug status to Vanda’s imsidolimab for pustular psoriasis

Reuters
·
May 27

Vanda Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 11

Vanda Pharmaceuticals Bets Big on Growth Pipeline

TIPRANKS
·
May 08

Vanda Pharmaceuticals to present at Bank of America Securities Global Health Care Conference

Reuters
·
May 08

Vanda Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 07

Vanda Pharma Q1 EPS $(0.82) Misses $(0.69) Estimate, Sales $51.718M Miss $54.978M Estimate

Benzinga
·
May 07

Vanda Q1 FY26 net loss widens to $48.6 million; revenue rises 3% to $51.7 million

Reuters
·
May 07

BRIEF-Vanda Pharmaceuticals Q1 EPS USD -0.82

Reuters
·
May 07

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

THOMSON REUTERS
·
May 07

Vanda Pharmaceuticals Q1 Revenue USD 51.718 Million VS. Ibes Estimate USD 55 Million

THOMSON REUTERS
·
May 07

Vanda Pharmaceuticals Outlook 2026 Total Revenues $240 Mln - $290 Million

THOMSON REUTERS
·
May 07

BRIEF-Vanda Pharmaceuticals Announces U.S. Commercial Availability Of Nereus™ (Tradipitant), The First New Pharmacologic Treatment For People With Motion Sickness In More Than 40 Years

Reuters
·
May 04

Vanda Pharmaceuticals Inc - Nereus Available at $85 per Dose Cash-Pay

THOMSON REUTERS
·
May 04

Vanda Pharmaceuticals Announces U.S. Commercial Availability of Nereus™ (Tradipitant), the First New Pharmacologic Treatment for People With Motion Sickness in More Than 40 Years

THOMSON REUTERS
·
May 04

BRIEF-Vanda Pharmaceuticals US Availability Of Nereus For People With Motion Sickness

Reuters
·
May 02

Vanda Pharmaceuticals announces commercial availability for Nereus

TIPRANKS
·
May 02

Vanda Pharmaceuticals: Standard List Price of $255 per Dose for Nereus

THOMSON REUTERS
·
May 02

Vanda Pharmaceuticals: Patients With Valid Prescription Can Access Nereus at Cash-Pay Price of $85 per Dose

THOMSON REUTERS
·
May 02